ArticleNature. Mental health2026
Patient-specific functional networks track early cognitive alterations and minor hallucinations in Parkinson's disease.
Article in Nature. Mental health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Minor hallucinations (MHs) affect up to 40% of patients with Parkinson's disease (PD) and are early indicators of cognitive decline. Unlike previous group-level studies, connectome-based brain fingerprinting enables the capture of individualized neural features. Leveraging this framework in a cross-sectional cohort of patients with Parkinson's disease with and without MHs using resting-state functional magnetic resonance imaging, here we show that each patient exhibits a unique brain fingerprint, irrespective of MH status. The most individualized features were associated with clinically relevant measures such as motor-symptom severity and cognitive performance. Patients with MHs showed a loss of individual-specific features in brain networks linked to cognitive health, whereas the cerebellar-to-cortex connectivity-typically less distinctive-became more prominent, emphasizing the role of somatosensory and motor integration in MH pathogenesis. Moreover, MH-related fingerprint regions mapped onto cortical territories with lower densities of neurotransmitter systems implicated in hallucinations. Overall, our fully data-driven findings reveal a distinct, patient-specific signature that differentiates patients with Parkinson's disease and MHs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.